News | June 24, 2024
EMA approves Biocon Biologics’ new mAbs facility in India
Renews GMP certifications for India and Malaysia sites
Renews GMP certifications for India and Malaysia sites
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
This clearance is a foundational step in Roche's commitment to enable routine clinical diagnosis with its digital pathology solutions
Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients
The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Department presents a detailed overview of the Pharma and MediTechsector and gives a detailed presentation on the activities of Department
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
This is the first peptide product approval from the USFDA received by Alembic Pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
